Clinical bottom line
Novel peptide-based therapies targeting coronary microvascular dysfunction (CMD) represent a promising, yet still investigational, approach to improving outcomes in patients with heart failure (HF), particularly those with nonischemic etiologies and preserved ejection fraction. CMD contributes to myocardial injury and impaired cardiac performance in HF, and early-phase evidence suggests that modulating microvascular function with peptide agents may ameliorate symptoms and potentially alter disease progression. However, clinical data remain limited, and these therapies warrant further validation before routine clinical adoption.
What the evidence shows
Coronary microvascular dysfunction is increasingly recognized as a key pathophysiological contributor to heart failure syndromes, especially HF with preserved ejection fraction (HFpEF) and nonischemic HF. Studies by Takashio et al. (2012) and Yamamuro et al. (2015) demonstrated that CMD is associated with increased cardiac troponin T release, a marker of ongoing myocardial injury, in patients with nonischemic HF. This suggests that microvascular impairment contributes to subclinical myocardial damage and fibrosis, which may exacerbate HF progression.
Further, Hori et al. (2011) showed that exercise-induced volume central shifts depress cardiac performance in HF patients with CMD, indicating that microvascular abnormalities impair the heart’s adaptive capacity to hemodynamic stress. Allan et al. (2019) linked CMD with adverse clinical outcomes in HFpEF, reinforcing the clinical relevance of microvascular pathology in this population.
Emerging peptide-based therapies aim to restore microvascular function by targeting endothelial signaling pathways, inflammation, and fibrosis. Although direct clinical trial data on these novel peptides remain sparse, reviews by Tang et al. (2022) and Favreau-Lessard et al. (2016) highlight their potential to improve myocardial perfusion, reduce fibrosis, and enhance cardiac function. Erhardsson et al. (2025) further emphasize the metabolic interplay in HF phenotypes, suggesting that peptide therapies modulating microvascular metabolism could offer tailored benefits.
Caveats and uncertainty
The current evidence base for peptide-based therapies targeting CMD in HF is largely preclinical or early-phase clinical, with a paucity of large randomized controlled trials. The heterogeneity of HF phenotypes, especially in HFpEF, complicates patient selection and outcome assessment. Biomarkers such as troponin T and imaging modalities for CMD remain imperfect surrogates, and their use to guide therapy requires further standardization.
Moreover, the long-term safety and efficacy of these novel peptides are not yet established. Potential off-target effects, immunogenicity, and optimal dosing regimens are areas needing rigorous investigation. The interplay between CMD and systemic metabolic dysfunction, as highlighted by Erhardsson et al. (2025), adds complexity to therapeutic targeting and may necessitate combination approaches.
How this may change practice
If ongoing and future studies confirm the efficacy and safety of peptide-based therapies targeting CMD, this could herald a new therapeutic paradigm for HF patients with microvascular impairment, particularly those with HFpEF who currently have limited treatment options. Clinicians may incorporate biomarker and imaging assessments of CMD into routine HF evaluation to identify candidates for such therapies.
In practice, these agents could complement existing HF treatments by addressing microvascular pathology and myocardial injury directly, potentially improving exercise tolerance, reducing hospitalizations, and slowing disease progression. However, until robust clinical trial data are available, these therapies should be considered investigational and used within research settings or specialized centers.